SCHEMBL6469880

SCHEMBL6469880

Nc1ccc(-c2nc(-c3ccncc3)c(-c3ccc(F)cc3)[nH]2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 15/20 1.00
MAPK12 P53778 15/20 1.00
MAPK11 Q15759 15/20 1.00
MAPK14 Q16539 15/20 1.00
GCGR P47871 13/20 1.00
ALOX5 P09917 12/20 1.00
PRKD3 O94806 3/20 0.86
MAP4K4 O95819 3/20 0.86
FRK P42685 3/20 0.86
MAPK9 P45984 3/20 0.86
CSNK1A1 P48729 3/20 0.86
CSNK1D P48730 3/20 0.86
GSK3B P49841 3/20 0.86
CLK4 Q9HAZ1 3/20 0.86
PTK6 Q13882 2/20 0.86
PRKD2 Q9BZL6 2/20 0.86
PRKACA P17612 2/20 0.75
SLK Q9H2G2 2/20 0.75
RIPK2 O43353 2/20 0.75
GMNN O75496 2/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2648969 1.00 MAPK13 (1.00) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL19868925 0.93 MAPK11 (1.00) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL15075603 0.93 MAPK11 (1.00) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL2650702 0.87 MAPK11 (1.00) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL16497639 0.87 MAPK14 (0.83) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL4552316 0.87 MAPK14 (1.00) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL9195042 0.87 MAPK14 (1.00) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL2650684 0.86 MAPK11 (1.00) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL19868954 0.86 MAPK14 (0.75) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL2648930 0.86 MAPK13 (1.00) MAPK13MAPK12MAPK11MAPK14GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050203155-A1 Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections AXXIMA PHARMACEUTICAL AG. (DE) 2005-09-15 US claimed
EP-1532118-A2 IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS Axxima Pharmaceuticals Aktiengesellschaft (DE) 2005-05-25 EP claimed
WO-2004005264-A2 IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS AXXIMA PHARMACEUTICALS AG (DE) 2004-01-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203155-A1 Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections CSNK1G1, CSNK1E, CSNK1D MAPK13 456/4885MAPK12 732/4885MAPK11 1215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.